MedPath

Bausch Health Companies Inc

🇨🇦Canada
Ownership
-
Employees
20.2K
Market Cap
$2.1B
Website
Introduction

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

stocktitan.net
·

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction

Bausch Health to present Xifaxan monotherapy vs. lactulose monotherapy for OHE recurrence risk reduction and mortality at ACG 2024, along with data on Xifaxan's impact on rehospitalizations in commercial and Medicare patients, and Plenvu's efficacy as a bowel preparation medication.
kilgorenewsherald.com
·

Gastrointestinal Diseases Therapeutics Market to Grow by USD 18.5 Billion from 2024-2028

The Global Gastrointestinal Diseases Therapeutics Market is projected to grow by USD 18.5 billion from 2024-2028, driven by increasing disease incidence and nutritional therapies. Key players include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, and others. High treatment costs pose a challenge.
globenewswire.com
·

Global Dermatology Drugs Market to Worth Over US$ 50.42

The global dermatology drugs market is projected to reach $50.42 billion by 2032 from $19.71 billion in 2023, driven by innovations in AI, genomics, and personalized medicine. Key players like Novartis, Pfizer, and Johnson & Johnson lead with advanced treatments, while Europe's high prevalence of skin conditions and robust healthcare infrastructure support market growth.
© Copyright 2025. All Rights Reserved by MedPath